Express News | AstraZeneca And Daiichi Sankyo's Datopotamab Deruxtecan Demonstrated Meaningfully Greater Magnitude Of Progression-free Survival Benefit In Non-Small Cell Lung Cancer Patients With TROP2 Biomarker In TROPION-Lung01 Phase 3 Trial

BenzingaSep 9 04:04 ET

Novel Computational Pathology-based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

BusinesswireSep 8 12:25 ET

The Year REIT's Reigned

Business TodaySep 6 10:32 ET

MIDF Positive on REITs' Earnings Prospects for 2H2024 Amid Bright Retail, Industrial Outlook

The Edge MarketsSep 6 05:20 ET

Timely On The Proposed Deposit For Home Buyers Initiative

Business TodaySep 3 21:33 ET

BIMB Expects Robust Property Sector in 2025, Maintains 'Overweight' Rating

The Edge MarketsSep 2 22:41 ET